These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Carbonic anhydrase inhibitors ameliorate the symptoms of hypokalaemic periodic paralysis in rats by opening the muscular Ca2+-activated-K+ channels. Tricarico D; Mele A; Conte Camerino D Neuromuscul Disord; 2006 Jan; 16(1):39-45. PubMed ID: 16368240 [TBL] [Abstract][Full Text] [Related]
14. [Periodic paralysis. Clinical analysis in 20 patients]. Tengan CH; De Oliveira AS; Gabbai AA Arq Neuropsiquiatr; 1994 Dec; 52(4):501-9. PubMed ID: 7611943 [TBL] [Abstract][Full Text] [Related]
15. A newly approved drug for a rare group of diseases: Dichlorphenamide for periodic paralysis. Fontaine B; Phillips LH Neurology; 2016 Apr; 86(15):1366-1367. PubMed ID: 26865522 [No Abstract] [Full Text] [Related]
16. Increased sarcolemma chloride conductance as one of the mechanisms of action of carbonic anhydrase inhibitors in muscle excitability disorders. Altamura C; Fonzino A; Tarantino N; Conte E; Liantonio A; Imbrici P; Carratù MR; Pierno S; Desaphy JF Exp Neurol; 2021 Aug; 342():113758. PubMed ID: 33991525 [TBL] [Abstract][Full Text] [Related]
17. Dichlorphenamide (Keveyis) for periodic paralysis. Med Lett Drugs Ther; 2016 Apr; 58(1492):50. PubMed ID: 27049510 [No Abstract] [Full Text] [Related]